Vancouver, British Columbia – December 16, 2011 – Sirona Biochem Corp. (TSX-V: SBM) (the “Company”), a biotechnology company specializing in carbohydrate chemistry technology, announced today that Mark Senner has stepped down from his role as President and a director.
“We thank Mark for his commitment and contributions over the past three years. He has been instrumental in building the Company to its current stage. The Company has five major projects that have evolved and will be taken to the next level. We greatly appreciate Mark’s efforts and wish him all the best in his future endeavours,” said Dr. Howard Verrico, Chief Executive Officer of Sirona Biochem. Dr. Verrico will, for the time being, take on the role of President in addition to his position as Chief Executive Officer of the Company.
Mark Senner joined Sirona Biochem in 2009. During his tenure, the Company completed its public listing on the TSX-Venture Exchange, acquired French-based TFChem and went from a single product emerging biotech company to that of a platform based technology company focused on fluorinated carbohydrate chemistry. Previously, he held positions at Biovail, Merck Frosst Canada, Bristol-Myers Squibb, Solvay and Novartis.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cancer vaccine antigens, cosmeceuticals and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of our carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.